Please login to the form below

tafamidis

This page shows the latest tafamidis news and features for those working in and with pharma, biotech and healthcare.

Alnylam gets EU nod for Onpattro amid pricing backlash

s Vyndaqel (tafamidis) has been registered in Europe since 2011 and costs in the region of $13, 000 per month. ... for tafamidis as a treatment for cardiomyopathy associated with hATTR amyloidosis after reporting positive results in the phase III

Latest news

Alnylam claims RNAi milestone with Onpattro approval

approved for that indication by the EMA in July and Pfizer’s Vyndaqel (tafamidis) which has been on the market since 2011 but was rejected by the FDA in 2012.
Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

The EMA said in a statement that having two drugs “considerably widens” the therapeutic options for hATTR amyloidosis, which include liver transplant, Pfizer’s Vyndaqel (tafamidis) and off-label non-steroidal
Pfizer’s flat sales focus investor attention on M&A

Vaccines for Clostridium difficile and staphylococcal infections and a new-generation Prevnar are making progress, along with rare disease therapies tafamidis for neuropathies and rivipansel for vaso-occlusive crises and tanezumab
Pfizer gets EU approval for neurodegenerative disease drug

worldwide. Vyndaqel (tafamidis; formerly Fx-1006A) becomes the first treatment approved anywhere in the world to treat the disease.
FDA refuses to file Pfizer NDA

Pfizer submitted the application for the drug, an oral compound called tafamidis, in February of this year. ... The FDA has not yet made any determination about the efficacy or safety of tafamidis, Pfizer stressed.

More from news
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

produced impressive data for its Vyndaqel (tafamidis). ... Onpattro looked to have the edge in terms of clinical data, but Pfizer has new data showing tafamidis is effective in treating patients with cardiomyopathy – the heart damage caused by the
Tough times for pharma in Portugal

spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Medical Writer: Salary TBC

Systematic Reviewer - Oxford: Negotiable

Senior Editorial Assistant – Greater Manchester: DOE

Healthcare Communications Account Directors x 2: Salary TBC

Associate Director: £75, 000-90, 000

Account Manager / Account Director: Competative

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Account Manager- Healthcare Advertising: Negotiable

Experienced Medical Writers: Competitive Salary and Benefits

Medical (Scientific) Director: £120, 000 benefits

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Account Manager: Negotiable

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Senior Account Manager: Competitive Salary Offered

Associate Medical Director: Excellent PTO, bonus and 401k package

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Editorial Manager - MedComms: DOE

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Principal Health Economist - North-West: Negotiable

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Business Director: Competitive Salary Offered

Subscribe to our email news alerts

PMHub

Add my company

Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls: ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...